MaaT Pharma To Present and Participate in Investor and Medical Conferences in September Lyon, France, September 4, 2024 – 7:30am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, announced that [...]
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Lyon, France, August 9, 2024 –6:00pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a [...]
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Lyon, France, July 5, 2024 –6:00pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a [...]
MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux Lyon, France, July 5, 2024 –6:00pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients [...]
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT [fancy-ul icon_type="standard_dash" color="Accent-Color" alignment="left" spacing="default"] Independent Data Safety and Monitoring Board (DSMB) recommended that the trial proceeds as planned without modifications. MaaT033 has shown to have an acceptable safety profile and was well tolerated in patients [...]
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16 Lyon, France, June 25th 2024 –6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to [...]
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer Lyon, France, June 24th 2024 –6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced the appointment [...]
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Lyon, France, June 10, 2024 –6:00pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a [...]
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting Lyon, France, May 29 2024 –6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today presents [...]
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]
MaaT Pharma To Present and Participate in Investor and Medical Conferences in September Lyon, France, September 4, 2024 – 7:30am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, announced that [...] 
